The Rare Disease Bank of Japan

establishment, current status and future challenges

Mayako Tada, Makoto Hirata, Mitsuho Sasaki, Ryuichi Sakate, Arihiro Kohara, Ichiro Takahashi, Yosuke Kameoka, Toru Masui, Akifumi Matsuyama

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Research on rare diseases cannot be performed without appropriate samples from patients with such diseases. Due to the limited number of such patients, securing biosamples of sufficient quality for extensive research is a challenge and represents an important barrier to the advancement of research on rare diseases. To tackle this problem, the Rare Disease Bank (RDB) was established in 2009 at the National Institute of Biomedical Innovation (NIBIO; currently, the National Institutes of Biomedical Innovation, Health and Nutrition in Japan). Since then, the RDB has focused on three objectives: (1) emphasizing the importance of collecting biosamples from patients with rare diseases, together with appropriate clinical information, from various medical facilities nationwide; (2) maintaining strict high-quality sample management standards; and (3) sharing biosamples with research scientists across Japan for the advancement of research on rare diseases. As of August 2017, the bank has collected 4147 biosamples from patients with rare diseases, including DNA, serum, plasma, and cell samples from various university hospitals and other medical institutions across the country, and provided various research institutions with 13,686 biosample aliquots from 2850 cases. In addition, the management committee has successfully established a bank system that provides high-quality biosamples together with the results of human leukocyte antigen analysis. It is anticipated that the RDB, through the collection and sharing of biosamples with the medical research community, will enhance the understanding, prevention, and treatment of rare diseases in Japan and the world at large.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalHuman Cell
DOIs
Publication statusAccepted/In press - 2018 Apr 2

Fingerprint

Rare Diseases
Japan
Research
HLA Antigens
Plasma Cells
Biomedical Research
DNA
Health
Serum

Keywords

  • Biobank
  • HLA analysis
  • Intractable disease
  • Quality control
  • The Rare Disease Bank

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research

Cite this

Tada, M., Hirata, M., Sasaki, M., Sakate, R., Kohara, A., Takahashi, I., ... Matsuyama, A. (Accepted/In press). The Rare Disease Bank of Japan: establishment, current status and future challenges. Human Cell, 1-6. https://doi.org/10.1007/s13577-018-0204-3

The Rare Disease Bank of Japan : establishment, current status and future challenges. / Tada, Mayako; Hirata, Makoto; Sasaki, Mitsuho; Sakate, Ryuichi; Kohara, Arihiro; Takahashi, Ichiro; Kameoka, Yosuke; Masui, Toru; Matsuyama, Akifumi.

In: Human Cell, 02.04.2018, p. 1-6.

Research output: Contribution to journalArticle

Tada, M, Hirata, M, Sasaki, M, Sakate, R, Kohara, A, Takahashi, I, Kameoka, Y, Masui, T & Matsuyama, A 2018, 'The Rare Disease Bank of Japan: establishment, current status and future challenges', Human Cell, pp. 1-6. https://doi.org/10.1007/s13577-018-0204-3
Tada, Mayako ; Hirata, Makoto ; Sasaki, Mitsuho ; Sakate, Ryuichi ; Kohara, Arihiro ; Takahashi, Ichiro ; Kameoka, Yosuke ; Masui, Toru ; Matsuyama, Akifumi. / The Rare Disease Bank of Japan : establishment, current status and future challenges. In: Human Cell. 2018 ; pp. 1-6.
@article{59ae506ce30d4a1397fdf0bbf7cec007,
title = "The Rare Disease Bank of Japan: establishment, current status and future challenges",
abstract = "Research on rare diseases cannot be performed without appropriate samples from patients with such diseases. Due to the limited number of such patients, securing biosamples of sufficient quality for extensive research is a challenge and represents an important barrier to the advancement of research on rare diseases. To tackle this problem, the Rare Disease Bank (RDB) was established in 2009 at the National Institute of Biomedical Innovation (NIBIO; currently, the National Institutes of Biomedical Innovation, Health and Nutrition in Japan). Since then, the RDB has focused on three objectives: (1) emphasizing the importance of collecting biosamples from patients with rare diseases, together with appropriate clinical information, from various medical facilities nationwide; (2) maintaining strict high-quality sample management standards; and (3) sharing biosamples with research scientists across Japan for the advancement of research on rare diseases. As of August 2017, the bank has collected 4147 biosamples from patients with rare diseases, including DNA, serum, plasma, and cell samples from various university hospitals and other medical institutions across the country, and provided various research institutions with 13,686 biosample aliquots from 2850 cases. In addition, the management committee has successfully established a bank system that provides high-quality biosamples together with the results of human leukocyte antigen analysis. It is anticipated that the RDB, through the collection and sharing of biosamples with the medical research community, will enhance the understanding, prevention, and treatment of rare diseases in Japan and the world at large.",
keywords = "Biobank, HLA analysis, Intractable disease, Quality control, The Rare Disease Bank",
author = "Mayako Tada and Makoto Hirata and Mitsuho Sasaki and Ryuichi Sakate and Arihiro Kohara and Ichiro Takahashi and Yosuke Kameoka and Toru Masui and Akifumi Matsuyama",
year = "2018",
month = "4",
day = "2",
doi = "10.1007/s13577-018-0204-3",
language = "English",
pages = "1--6",
journal = "Human Cell",
issn = "0914-7470",
publisher = "Springer Heidelberg",

}

TY - JOUR

T1 - The Rare Disease Bank of Japan

T2 - establishment, current status and future challenges

AU - Tada, Mayako

AU - Hirata, Makoto

AU - Sasaki, Mitsuho

AU - Sakate, Ryuichi

AU - Kohara, Arihiro

AU - Takahashi, Ichiro

AU - Kameoka, Yosuke

AU - Masui, Toru

AU - Matsuyama, Akifumi

PY - 2018/4/2

Y1 - 2018/4/2

N2 - Research on rare diseases cannot be performed without appropriate samples from patients with such diseases. Due to the limited number of such patients, securing biosamples of sufficient quality for extensive research is a challenge and represents an important barrier to the advancement of research on rare diseases. To tackle this problem, the Rare Disease Bank (RDB) was established in 2009 at the National Institute of Biomedical Innovation (NIBIO; currently, the National Institutes of Biomedical Innovation, Health and Nutrition in Japan). Since then, the RDB has focused on three objectives: (1) emphasizing the importance of collecting biosamples from patients with rare diseases, together with appropriate clinical information, from various medical facilities nationwide; (2) maintaining strict high-quality sample management standards; and (3) sharing biosamples with research scientists across Japan for the advancement of research on rare diseases. As of August 2017, the bank has collected 4147 biosamples from patients with rare diseases, including DNA, serum, plasma, and cell samples from various university hospitals and other medical institutions across the country, and provided various research institutions with 13,686 biosample aliquots from 2850 cases. In addition, the management committee has successfully established a bank system that provides high-quality biosamples together with the results of human leukocyte antigen analysis. It is anticipated that the RDB, through the collection and sharing of biosamples with the medical research community, will enhance the understanding, prevention, and treatment of rare diseases in Japan and the world at large.

AB - Research on rare diseases cannot be performed without appropriate samples from patients with such diseases. Due to the limited number of such patients, securing biosamples of sufficient quality for extensive research is a challenge and represents an important barrier to the advancement of research on rare diseases. To tackle this problem, the Rare Disease Bank (RDB) was established in 2009 at the National Institute of Biomedical Innovation (NIBIO; currently, the National Institutes of Biomedical Innovation, Health and Nutrition in Japan). Since then, the RDB has focused on three objectives: (1) emphasizing the importance of collecting biosamples from patients with rare diseases, together with appropriate clinical information, from various medical facilities nationwide; (2) maintaining strict high-quality sample management standards; and (3) sharing biosamples with research scientists across Japan for the advancement of research on rare diseases. As of August 2017, the bank has collected 4147 biosamples from patients with rare diseases, including DNA, serum, plasma, and cell samples from various university hospitals and other medical institutions across the country, and provided various research institutions with 13,686 biosample aliquots from 2850 cases. In addition, the management committee has successfully established a bank system that provides high-quality biosamples together with the results of human leukocyte antigen analysis. It is anticipated that the RDB, through the collection and sharing of biosamples with the medical research community, will enhance the understanding, prevention, and treatment of rare diseases in Japan and the world at large.

KW - Biobank

KW - HLA analysis

KW - Intractable disease

KW - Quality control

KW - The Rare Disease Bank

UR - http://www.scopus.com/inward/record.url?scp=85044777642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044777642&partnerID=8YFLogxK

U2 - 10.1007/s13577-018-0204-3

DO - 10.1007/s13577-018-0204-3

M3 - Article

SP - 1

EP - 6

JO - Human Cell

JF - Human Cell

SN - 0914-7470

ER -